Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ARE
ARE logo

ARE Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Alexandria Real Estate Equities Inc (ARE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
47.900
1 Day change
-2.20%
52 Week Range
88.240
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Based on the provided data, Alexandria Real Estate Equities Inc (ARE) is not a strong buy for a beginner investor with a long-term strategy. The stock lacks clear positive catalysts, has mixed financial performance, and faces industry-specific challenges. Holding or exploring other investment opportunities may be more prudent.

Technical Analysis

The MACD is positive and expanding, suggesting bullish momentum. However, the RSI is neutral at 70.607, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near resistance levels (R1: 47.884, R2: 49.656), which could limit upside potential.

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
5

Positive Catalysts

  • No significant positive catalysts identified. The MACD indicates some bullish momentum, but this is not strongly supported by other indicators.

Neutral/Negative Catalysts

  • Downgrades from analysts citing elevated dilution, systemic pressures on the life sciences industry, and uncertainty around tenant demand. Financial performance shows declining revenue and gross margin. Analysts have reduced price targets, and there are no significant insider or hedge fund trades to indicate confidence.

Financial Performance

In Q4 2025, revenue dropped by -18.13% YoY, gross margin decreased by -42.67% YoY, and net income increased significantly but remains negative (-$1.08 billion). EPS also improved but is still negative at -6.35.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have downgraded the stock and reduced price targets, citing challenges in the life sciences industry and limited visibility into demand recovery. The consensus rating is Neutral, with price targets ranging from $52 to $61, indicating limited upside.

Wall Street analysts forecast ARE stock price to rise
15 Analyst Rating
Wall Street analysts forecast ARE stock price to rise
3 Buy
12 Hold
0 Sell
Hold
Current: 48.980
sliders
Low
41
Averages
56.85
High
67
Current: 48.980
sliders
Low
41
Averages
56.85
High
67
BMO Capital
Outperform -> Market Perform
downgrade
$65 -> $52
AI Analysis
2026-03-25
Reason
BMO Capital
Price Target
$65 -> $52
AI Analysis
2026-03-25
downgrade
Outperform -> Market Perform
Reason
BMO Capital downgraded Alexandria Real Estate to Market Perform from Outperform with a price target of $52, down from $65. The firm cites elevated dilution from the company's asset sales and increased uncertainty on a demand recovery in life sciences for the downgrade. Alexandria's asset sales are being overshadowed by higher interest rates and the "looming AI-threat" on lab office demand, the analyst tells investors in a research note. BMO favors companies with "solid earnings growth," which it says is unlikely for Alexandria.
JPMorgan
Neutral
downgrade
$63 -> $57
2026-03-10
Reason
JPMorgan
Price Target
$63 -> $57
2026-03-10
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Alexandria Real Estate to $57 from $63 and keeps a Neutral rating on the shares. The firm updated the company's model.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ARE
Unlock Now

People Also Watch